Abstract: The invention concerns the identification and use of neogenin receptor-binding domains of members of the repulsive guidance molecule (RGM) protein family as well as polypeptide fragments derived therefrom. The inventive domains, i.e. peptide fragments are suited as agents for the active or passive immunization of individuals as well as diagnostic and therapeutic agents for use with diseases or pathological conditions in whose origin or progression, a member of the RGM family and a cellular receptor assigned to this molecule are involved. The invention also concerns monoclonal and polyclonal antibodies directed against the inventive binding domains and against the polypeptides derived therefrom, and to method for producing the inventive domains, polypeptides and antibodies.
Type:
Grant
Filed:
September 29, 2006
Date of Patent:
December 9, 2014
Assignee:
AbbVie Deutschland GmbH & Co. KG
Inventors:
Bernhard K. Muller, Gregor Schaffar, Reinhold Mueller
Abstract: The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of S. mansoni (Sm14) or related FABPs (Fatty Acid Binding Proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity. More particularly, the present invention relates to a method for constructing active peptide fragments, peptide fragments, immunogenic composition and diagnostic kit using peptide fragments of the present invention.
Type:
Grant
Filed:
November 1, 2012
Date of Patent:
December 9, 2014
Assignee:
Fundação Oswaldo Cruz—FIOCRUZ
Inventors:
Miriam Tendler, Richard Charles Garratt, Naftale Katz, Andrew John George Simpson, Frank Jefferson Alarcon de Barrientos, Mônica Magno Vilar, Marilia Sirianni dos Santos Almeida
Abstract: The present invention broadly provides novel peptides that can be used to form hydrogels. The peptides are short (preferably 30 amino acid residues or less) and include hydrophilic and hydrophobic segments joined by a turning segment. The hydrogels are formed by altering the pH of a solution of these peptides to an acidic level, or by introducing a source of ions into a solution of these peptides. The resulting hydrogels are shear thinning gels that have high storage moduli and high rates of recovery after destruction. They find use in medical applications, including tissue engineering.
Abstract: A method for stabilizing an alpha helix of a polypeptide includes steps of: (1) connecting an unnatural amino acid to an amino terminus of the polypeptide and end-capping via an acetylation; (2) processing a product of the step (1) with a thiolene reaction and obtaining a polypeptide compound having a modification of thioether side chains; (3) oxidizing the polypeptide compound having the modification of the thioether side chains, and obtaining a polypeptide compound having a modification of R-configured sulfoxide side chains or S-configured sulfoxide side chains; (4) separating and purifying a product of the step (3), and obtaining the modification of the R-configured sulfoxide side chains. CD diagrams show that, via chiral sulfoxide side chains, the method has good performance on stabilizing the alpha helix of the polypeptide and good tolerance to a polypeptide sequence.
Type:
Application
Filed:
January 26, 2014
Publication date:
December 4, 2014
Applicant:
Peking University Shenzhen Graduate School
Abstract: The present disclosure provides a composition for radiation exposure diagnosis including an agent for measuring an expression level of an insulin-like growth factor-binding protein-5 (IGFBP-5) gene at an mRNA or the protein and a kit for radiation exposure diagnosis. Methods of diagnosing radiation exposure as well as methods for screening an agent for enhancing radiation sensitivity or for radiation protection are disclosed. Also provided are compositions for enhancing radiation sensitivity and/or radiation protection.
Type:
Application
Filed:
May 9, 2012
Publication date:
December 4, 2014
Applicant:
Korea Institute of Radiological & Medical Sciences
Inventors:
Kwang Seok Kim, Sang Woo Bae, Kyu Jin Choi, Eun Sook Kim
Abstract: The present invention is directed to a method of detecting intact fibrinogen, comprising the steps of: a) providing a sample containing at least some fibrinogen optionally converted at least in part to fibrin, and optionally containing thrombin; b) solubilizing the sample in a solubilizing solution that inhibits thrombin activity; c) after optional SDS-PAGE transferring/applying a portion of said sample to a protein-binding membrane; d) reacting the fibrinogen with a primary monoclonal antibody capable of binding to fibrinopeptide A moiety; and e) detecting the quantity of intact fibrinogen in the sample by quantifying the amount of the bound primary monoclonal antibody.
Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
Type:
Grant
Filed:
November 3, 2009
Date of Patent:
December 2, 2014
Assignee:
Molecular Partner AG
Inventors:
Hans Kasper Binz, Patrik Forrer, Michael Tobias Stumpp
Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.
Type:
Grant
Filed:
April 30, 2012
Date of Patent:
December 2, 2014
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Yung-Fu Chang, Raghavan U. M. Palaniappan
Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
December 2, 2014
Assignee:
The Regents of the University of Michigan
Inventors:
Thomas D. Wang, Sharon Miller, Bishnu Joshi
Abstract: A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from Trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.
Abstract: Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against Plasmodium falciparum, the most severe form of malaria. Conjugates of ookinete surface protein Pvs25 for use as a vaccine against Plasmodium vivax are also provided. Methods for preparing the conjugates, which comprise the ookinete surface protein bound onto itself or onto another protein by a linking group, are also provided.
Type:
Grant
Filed:
January 25, 2013
Date of Patent:
December 2, 2014
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Rachel Schneerson, Joanna Kubler-Kielb, Yimin Wu, Louis Miller, Fathy Majadly, John B. Robbins
Abstract: Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen.
Type:
Grant
Filed:
July 21, 2008
Date of Patent:
December 2, 2014
Assignee:
Duke University
Inventors:
Robert J. Schmittling, Gary E. Archer, John H. Sampson, Darell D. Bigner
Abstract: The present invention provides selective modification of polypeptide sequences with electron transfer moieties. The resulting polypeptide assemblies represent a novel class of electron transfer complexes that are capable of transferring electrons over very long distances at fast rates. These complexes possess unique structural features which enable the production of bioconductors and photoactive probes.
Type:
Grant
Filed:
April 19, 2010
Date of Patent:
December 2, 2014
Assignee:
Research Foundation of The City University of New York
Abstract: The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X1 G Q S X2 G X3 G X4 G X5 G X6 G X7 G K G K S X8 D K Q X9 K P G G P W X10 P E P (SEQ ID No. 1), wherein the amino acids X1-X10 are selected independently from an arginine residue or a citrulline residue and at least one of X1-X10 is a citrulline residue, or a functional fragment thereof and uses thereof.
Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.
Type:
Grant
Filed:
April 9, 2008
Date of Patent:
November 25, 2014
Assignee:
The General Hospital Corporation
Inventors:
Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.
Type:
Grant
Filed:
March 18, 2010
Date of Patent:
November 25, 2014
Assignee:
Hanmi Science Co., Ltd
Inventors:
Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
Type:
Grant
Filed:
September 5, 2008
Date of Patent:
November 25, 2014
Assignee:
Novo Nordisk A/S
Inventors:
Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Steffen Reedtz-Runge, Henning Thøgersen, Ingrid Pettersson
Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.
Abstract: Methods for building peptide chains containing sulfonyl modified amines at the N-terminus, or, within amino acid side chains, of a growing peptide in a solid-phase peptide synthesis are described. Further, compositions having a sulfonyl modified amine attached to the N-terminus, or within an amino acid side chain, of a polypeptide containing three or more amino acid residues are described.
Type:
Grant
Filed:
August 28, 2012
Date of Patent:
November 25, 2014
Assignee:
The University of Toledo
Inventors:
Steven J. Sucheck, Rommel S. Talan, Partha Karmakar
Abstract: A method for nasal administration of a pharmaceutical composition comprising a hydrophilic bioactive substance and any one of (a) to (c): (a) a peptide having the amino acid sequence shown in SEQ ID NO:1; (b) a peptide having the same amino acid sequence as shown in SEQ ID NO:1 except that one or several amino acids are deleted, substituted and/or added, the peptide having nasal mucosal permeability; (c) a peptide having an amino acid sequence represented by the reverse sequence of (a) or (b), the peptide having nasal mucosal permeability, with the proviso that a C-terminal amidated peptide is excluded. A hydrophilic bioactive substance having a low transmucosal absorption capability which has conventionally been able to be administered by only injection can be nasally administered. Such a pharmaceutical composition is useful for improvement of the pain and the inconvenience of patients caused by administration by injection.
Type:
Grant
Filed:
February 27, 2009
Date of Patent:
November 25, 2014
Assignee:
Toray Industries, Inc.
Inventors:
Mariko Morishita, Kozo Takayama, Reiji Nishio, Nobuo Ida
Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
Abstract: The invention relates to a method for homogeneous solution phase peptide synthesis (HSPPS) of a N-terminal peptide fragment PEP-N and a C-terminal peptide fragment C-PEP, with C-PEP carrying a specific diketopiperazine (DKP) comprising C-terminal protecting group, which contains a handle group HG, with HG being connected to the C-terminus of the peptide fragmcnt; thereby this specific DKP comprising C-terminal protecting group can be selectively cleaved from the peptide as a conventionally used C-terminal protecting group. By the use of this DKP and HG comprising C-terminal protecting group, certain process steps in convergent peptide synthesis based on a combination of HSPPS and solid phase peptide synthesis (SPPS) can be avoided.
Abstract: The present invention relates to hydrogels and methods for producing and using the same. In particular, some embodiments of the invention relate to hydrogels and methods for patterning the same.
Type:
Application
Filed:
April 21, 2014
Publication date:
November 20, 2014
Applicant:
The Regents of the University of Colorado, a body corporate
Inventors:
Kristi Anseth, Brian Polizzotti, Cole DeForest
Abstract: Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.
Type:
Grant
Filed:
March 27, 2012
Date of Patent:
November 18, 2014
Assignee:
Nektar Therapeutics
Inventors:
Mary J. Bossard, Michael D. Bentley, Ping Zhang
Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.
Type:
Grant
Filed:
February 23, 2012
Date of Patent:
November 18, 2014
Assignee:
Oncothyreon Inc.
Inventors:
Scott Peterson, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
Abstract: Recombinant proteins for siRNA delivery and a composition including same. These recombinant proteins include a p19 RNA binding protein and a target oriented peptide and can secure the stability of siRNAs from external attacks such as various degradation enzymes, have selective binding affinity to cancer cells by virtue of target-oriented peptides having various cancer cells as their target, and silence target genes by effectively delivering the siRNAs to cells and biological tissues by the release of the siRNAs to the cytoplasms after the cell penetration thereof. Therefore, they are expected to be effectively employed as siRNA delivery vehicles for siRNA therapeutic agents, cell-based drug screening compositions and research.
Type:
Grant
Filed:
January 16, 2013
Date of Patent:
November 18, 2014
Assignee:
Korea Institute of Science and Technology
Abstract: A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.
Abstract: Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject.
Type:
Grant
Filed:
May 29, 2009
Date of Patent:
November 18, 2014
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Joachim Struck, Stephanus Johannes Bakker
Abstract: C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.
Type:
Grant
Filed:
November 9, 2009
Date of Patent:
November 18, 2014
Assignee:
The General Hospital Corporation
Inventors:
Joel F. Habener, Tatsuya Yano, Eva Tomas Falco
Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.
Abstract: A modified peptide derived from matrix protein 2 (hereinafter also referred to as “M2”), one of surface layer proteins of influenza virus, and a method for utilization of the modified peptide are provided. A peptide (hereinafter also referred to as “M2eC peptide”) that is made up by inserting cysteine residue(s) into a peptide (hereinafter also referred to as “M2e”) consisting of 23 amino acid residues of from positions No. 2 to No.
Type:
Grant
Filed:
August 23, 2010
Date of Patent:
November 11, 2014
Assignee:
The Chemo-Sero-Therapeutic Research Institute
Abstract: The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which a heavy-chain low-molecular-weight antibody and a light-chain low-molecular-weight antibody are separately immobilized, the two or more antibody immobilized regions each being included in an independent manner, the heavy-chain low-molecular-weight antibody including a heavy-chain variable region, the light-chain low-molecular-weight antibody including a light-chain variable region, the heavy-chain low-molecular-weight antibody and the light-chain low-molecular-weight antibody each being derived from an antibody recognizing a different antigen.
Type:
Grant
Filed:
February 15, 2011
Date of Patent:
November 11, 2014
Assignees:
National University Corporation Kyoto Institute of Technology, Denka Seiken Co., Ltd.
Inventors:
Yoichi Kumada, Michimasa Kishimoto, Kyoko Hamasaki, Aya Nakagawa
Abstract: Bacteriorhodopsin protein variants and methods using the bacteriorhodopsin variants for performance in holographic and three-dimensional (3D) memory storage devices are described. The amino acid and chemical modifications of bacteriorhodopsin provided herein achieve greatly enhanced protein performance. The memory storage devices write, read and erase data proficiently. The bacteriorhodopsin protein variants are useful in optical memory storage and associative processor systems. Irradiation of the light-sensitive protein with light of known wavelength causes the protein to switch between different states. The variants enter the branched photocycle via a single or a two photon process and form the permanent ‘Q’ state more efficiently than the wild-type bacteriorhodopsin protein. This branching photocycle of the variants is exploited in the fabrication of 3D memory storage devices.
Type:
Grant
Filed:
January 14, 2009
Date of Patent:
November 11, 2014
Assignee:
University of Connecticut
Inventors:
Robert R. Birge, Rekha Rangarajan, Kristina Nicole McCleary
Abstract: The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
Abstract: The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca2+ dependency, specific activity, and solubility, in particular under production conditions.
Abstract: The present embodiments provide for compositions and methods that regulate microRNA-binding protein-mediated miRNA biogensis; for example Lin28-mediated biogenesis of let-7; and in particular Lin28A-recruited 3? terminal uridylyl transferase (TUTase) uridylation of pre-let-7. A particular embodiment provide compositions and methods for screening for agents that inhibit TUTase-dependent Lin28A-mediated repression of let-7 miRNA.
Type:
Application
Filed:
May 2, 2014
Publication date:
November 6, 2014
Applicants:
Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
Richard I. Gregory, Elena Piskounova, Dimitrios Iliopoulos
Abstract: Affinity tags and ligands comprising a PDZ domain peptide and a PDZ binding carboxy terminal peptide and related engineered protein, engineered labels, compositions, methods and systems.
Abstract: The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.
Type:
Application
Filed:
May 19, 2014
Publication date:
November 6, 2014
Applicant:
Mayo Foundation for Medical Education and Research
Inventors:
Geoffry L. Curran, Gobinda Sarkar, Joseph F. Poduslo, Robert B. Jenkins, Val J. Lowe, Erik W. Mahlum
Abstract: The invention relates to peptide derivatives (peptides and pseudo-peptides) and the use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides of the invention can be used, in particular, to vectorize, generally in the form of prodrug conjugates, molecules of pharmaceutical or diagnostic interest such as, for example, therapeutic molecules, imaging or diagnostic agents, or molecular probes, across cell membranes of different tissues or organs, healthy or pathologic, and in particular to enable their transport across physiological barriers of the nervous system such as the Blood brain barrier (BBB), Blood-spinal cord barrier (BSCB), or Blood-retinal barrier (BRB).
Type:
Grant
Filed:
October 19, 2012
Date of Patent:
November 4, 2014
Assignees:
Vect-Horus, Centre National de la Recherche Scientifique, Universite D'Aix-Marseille
Inventors:
Patrick Vlieghe, Marion David, Yves Molino, Michel Khrestchatisky
Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.
Type:
Grant
Filed:
March 20, 2012
Date of Patent:
November 4, 2014
Assignee:
The Regents of the University of California
Abstract: The present invention relates to a process for the production of fine chemicals in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof. The present invention relates further to a process for the control of the production of fine chemicals in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antisense molecules, antibodies, host cells, plant tissue, propagation material, harvested material, plants, microorganisms as well as agricultural compositions and to their use.
Type:
Application
Filed:
September 22, 2011
Publication date:
October 30, 2014
Applicant:
Metanomics GmbH
Inventors:
Gunnar Plesch, Piotr Puzio, Astrid Blau, Ralf Looser, Birgit Wendel, Beate Kamlage, Oliver Schmitz
Abstract: Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease.
Type:
Grant
Filed:
January 26, 2011
Date of Patent:
October 28, 2014
Assignee:
Children's Hospital Medical Center
Inventors:
Rohit Kohli, Stavra A. Xanthakos, Michael V. Miles
Abstract: A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabinogalactan-proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.
Abstract: The invention provides compositions and methods of use thereof for labeling peptide and proteins in vitro or in vivo. The methods described herein employ lipoic acid ligase or mutants thereof, and lipoic acid analogs recognized by lipoic acid ligase and lipoic acid ligase mutants.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
October 28, 2014
Assignee:
Massachusetts Institute of Technology
Inventors:
Alice Y. Ting, Marta Fernandez Suarez, Hemanta Baruah
Abstract: The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.
Type:
Grant
Filed:
March 21, 2011
Date of Patent:
October 28, 2014
Assignee:
Yale University
Inventors:
Catalin S. Buhimschi, Irina Buhimschi, Errol Norwitz
Abstract: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
Type:
Grant
Filed:
September 16, 2010
Date of Patent:
October 28, 2014
Assignees:
Human Matrix Sciences, LLC, The Hospital for Sick Children
Inventors:
Felipe Jimenez, Thomas F. Mitts, Aleksander Hinek
Abstract: The present invention relates to assays and methods for the detection of transthyretin and its isoforms. Specifically, the assays and methods of the present invention embrace liquid chromatography and mass spectrometry. The present invention also relates to unique peptides and peptide variants useful in the assays and methods.
Type:
Application
Filed:
November 16, 2012
Publication date:
October 23, 2014
Inventors:
James Butler, Renta Hutabarat, Rene Alvarez, Bob Xiong, Lily Y.T. Li
Abstract: The present invention relates to nanofibers. In particular, the present invention provides aligned nanofiber bundle assemblies. In some embodiments, the aligned nanofiber bundle assemblies are used for tissue regeneration, controlled growth of cells, and related methods (e.g., diagnostic methods, research methods, drug screening).
Type:
Application
Filed:
July 8, 2014
Publication date:
October 23, 2014
Inventors:
Samuel I. Stupp, Shuming Zhang, Alvaro Mata, Megan A. Greenfield